Van Hulzen Asset Management, LLC Bio N Tech Se Transaction History

Van Hulzen Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$118.43 - $186.05 $473,720 - $744,200	-4,000 Reduced 49.99%	4,001 $601,000
Q3 2022 Nov 08, 2022	BUY	$127.65 - $183.11 $510,600 - $732,440	4,000 Added 99.98%	8,001 $1.08 Million
Q2 2022 Aug 04, 2022	BUY	$123.25 - $186.24 $493,123 - $745,146	4,001 New	4,001 $597,000
Q1 2022 May 20, 2022	SELL	$126.25 - $231.85 $1.26 Million - $2.32 Million	-10,000 Closed	0 $0
Q4 2021 Feb 04, 2022	BUY	$216.64 - $362.52 $1.13 Million - $1.89 Million	5,200 Added 108.33%	10,000 $2.58 Million
Q3 2021 Nov 12, 2021	BUY	$205.93 - $447.23 $224,051 - $486,586	1,088 Added 29.31%	4,800 $1.31 Million
Q2 2021 Aug 06, 2021	BUY	$113.32 - $241.49 $420,643 - $896,410	3,712 New	3,712 $831,000

358

38.4M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $29.6B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Van Hulzen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Van Hulzen Asset Management, LLC with notifications on news.